Agios Pharmaceuticals Inc.
Agios develops targeted metabolic oncology drugs, notably PYRUKYND, an oral PK activator approved for PK deficiency and in phase 3 for sickle cell disease, with a robust pipeline in myelodysplastic syndrome, thalassemia and rare metabolic disorders.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Manufacturing
- Industry: Pharmaceutical Manufacturing
- Employees: 486
- HQ: Cambridge
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.